high mobility group nucleosome binding domain 1 pseudogene 17Genealiases: []
Q-omics provides the consensus-scored HMGN1P17 profile across patient tissues and cancer cell-line models. HMGN1P17 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HMGN1P17 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HMGN1P17 RNA expression shows 8,630 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, KIRC, and KIRP as cancer lineages where HMGN1P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN1P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN1P17 survival associations across molecular data types. HMGN1P17 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN1P17 RNA expression–survival associations across cancer types. High HMGN1P17 expression shows unfavorable associations in LIHC, UCS, UCEC, TGCT and COAD, but favorable associations in LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HMGN1P17 RNA expression.
This table summarizes HMGN1P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN1P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN1P17 shows lower tumor expression in KIRC, KICH, KIRP and THCA and higher tumor expression in BRCA and STAD. The KIRC box plot shows higher HMGN1P17 RNA expression in normal versus tumor tissue (log2 FC = −2.003, t-test p < 0.001).
This table shows molecular features associated with HMGN1P17 in patient tissues and cancer cell lines. In patient samples, HMGN1P17 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
